Kornimate/medical-research-clean huggingface dataset:
study of effectiveness of rmv (repeated muscle vibration) in knee osteoarthritis

Conditions: Knee Osteoarthritis

Summary: the rehabilitation protocols in knee osteoarthritis are often difficult to be applied in elderly patients because they are long lasting and need the constant participation of patients. to rapidly improve the motor performances of patients it is possible to use the mechanical vibration applied to individual muscles using a protocol called "repeated muscle vibration" (rmv). the purpose of this single-blind randomized placebo-controlled study is to evaluate the effectiveness of the repeated muscle vibration (rmv) in terms of increasing the ability of the patients affected by knee osteoarthritis, compared to an ineffective treatment, considered as a placebo. each subject, randomly assigned to either the group 1 (study group) or placebo-treatment (group 2)is administered 3 daily applications of rmv of 10 minutes each, for 3 consecutive days. between two successive applications it's observed a break of at least 15 seconds. the probe of the specific instrument (cro ® system) is placed near the supero-medial margin of the patella, on both quadriceps. patients in group 2 (control group) are subjected to a treatment with muscle released in which the probe of the same instrument is approached to the quadriceps, without making contact. the instrument in these conditions emits a buzz but not provokes muscle vibration. the primary outcome of the study is to determine the changing in patients' ability (as measured by womac scale = western ontario and mcmaster universities osteoarthritis index) . the secondary outcomes of the study are the assessment of changing of patients' balance and risk of falling (as measured by the tinetti scale) and assessment of changing of patients' quality of life (as measured by eq-vas= euroquality of life-vas scale).outcome measures are administered at baseline (t0), at the end of the treatment protocol (t1), at 1 month (t2), 3 months (t3) after the end of treatment and 6 months (t4) after the end of the treatment.


Eligibility criteria:
inclusion criteria: * knee osteoarthritis exclusion criteria: * neurologic disease involving the lower limbs or causing balance problems * systemic inflammatory diseases * diabetic neuropathy * severe heart disease. * acute infections or bone tuberculosis * prosthetic lower limbs * history of surgery on the affected knee in the last year * history of cancer * cognitive impairment

Keywords: knee, osteoarthritis, muscle vibration
multidrug resistance after trabeculectomy with mitomycin c

Conditions: Glaucoma; Trabeculectomy

Summary: we investigate whether mitomycin c treatment during previous filtration surgery induces p-glycoprotein expression.

despite the adjuvant use of mitomycin c during trabeculectomy, short-term and long-term failures still occur. we investigate whether mitomycin c treatment during previous trabeculectomy induces p-glycoprotein expression. expression of p-glycoprotein is analysed in surgically removed tenon tissue using immunohistochemistry.

Eligibility criteria:
inclusion criteria: * patients with planned trabeculectomy for elevated eye pressure * one third of patients without previous trabeculectomy * two thirds of patients with previous trabeculectomy (one third with and one third without the use of mitomycin c) exclusion criteria: * patients not requiring surgery * patients with planned surgery for elevated eye pressure other than trabeculectomy

Keywords: glaucoma drug resistance, multiple trabeculectomy
the effect of sequential feeding for circadian rhythm and gut flora rhythm in critically ill patients

Conditions: Feeding Patterns; Critical Illness; Circadian Rhythm Disorders

Summary: circadian rhythms plays an important role for healthy. and critical illness contributes to the disruption of circadian rhythms. not only right but also feeding can affect the circadian clock gene expression. in a investigators' previous study, some metabolic indicators (the albumin level, total cholesterol level and total bile acid level) and the increases in lymphocyte counts in the sequential feeding group were different from those in the continuous feeding group. investigators think sequential feeding may adjust circadian clock gene expression for its effect on metabolism and immunity. moreover, sequential feeding did alter the abundances of some gut microbes to some degree in the investigators' previous study. investigators think sequential feeding may adjust gut flora rhythms.


Eligibility criteria:
inclusion criteria: * patients newly admitted to icu were eligible for inclusion. exclusion criteria: * an estimated feeding time of less than 10 days in icu; * diabetes; * gastrointestinal disease (gastrointestinal surgery, gastrointestinal bleeding, pancreatitis, crohn's disease, ulcerative colitis, irritable bowel syndrome); * inability to tolerate ≥80% of the nutrition target calories (25-30 kcal/kg/d) with enteral feeding through gastric tube; * the ability to eat orally at admission.
extracellular vesicles as biomarkers for chronic renal failure

Conditions: Chronic Renal Failure; Urinary Extracellular Vesicle

Summary: the recent discovery of extracellular vesicles (ev) as a mechanism of intercellular communication has made it possible to develop a new field of health research and could bring new information on the pathological mechanisms of renal diseases. definition of physiologic and pathologic values of urinary extracellular vesicles (evu) between healthy subjects and chronic kidney diseases (ckd) patients could be a new tool for follow up of renal diseases. ev are found in all biological fluids including urine, that's why they are increasingly analyzed in renal pathologies. the main objective of this study is to determine the physiological values and the pathological thresholds of evu.


Eligibility criteria:
inclusion criteria: * subject \> 18 years old * healthy subjects : no medical history, in particular cardiovascular, without drug treatment, without proteinuria, normal bmi * crf patients : egfr estimated according to the mrdr formula less than 89 ml/min/1,73m² exclusion criteria: * patients under dialysis protocols * renal transplant patients

Keywords: urinary extracellular vesicle chronic renal failure
echocardiographic evaluation of the change on pulmonary blood flow and cardiac function induced by capnothorax during one lung ventilation

Conditions: Mediastinal Tumors

Summary: video-assisted thoracoscopic extended thymectomy (vatet) is a minimally-invasive method for excision of mediastinal mass instead of open thymectomy. the iatrogenic capnothorax with one-lung ventilation during vatet may cause hemodynamic instability due to the compression of intrathoracic structures. the purpose of this study is to evaluate the effects of capnothorax on the pulmonary blood flow and cardiac function during the vatet by using the transesophageal echocardiography.

video-assisted thoracoscopic extended thymectomy (vatet) is a minimally-invasive method for excision of mediastinal mass instead of open thymectomy. the iatrogenic capnothorax with one-lung ventilation during vatet may cause hemodynamic instability due to the compression of intrathoracic structures. the purpose of this study is to evaluate the effects of capnothorax on the pulmonary blood flow and cardiac function during the vatet by using the transesophageal echocardiography

Eligibility criteria:
inclusion criteria: 1. above 20 years of age. 2. american society of anesthesiologists (asa) physical status i, ii, iii. 3. thoracic surgical procedure (video-assisted thoracoscopic extended thymectomy ) exclusion criteria: 1. severe functional liver or kidney disease 2. diagnosed hf ( nyha class \>3) 3. arrhythmia or received treatment with antiarrhythmic drug . 4. exceed bmi \> 30 kg/ m2 5. copd 6. pathologic esophageal lesion (esophageal stricture or varix ) 7. pregnancy

Keywords: mediastinal mass, one-lung ventilation, capnothorax, transesophageal echocardiography
mps ii immunophenotyping

Conditions: MPS II; Mucopolysaccharidosis II; Hunter Syndrome

Summary: the purpose of this study is to investigate how participant's body's immune system responds to idursulfase, an enzyme replacement therapy (ert) and find out which types of immune cells are involved in causing untoward responses to the ert so that the investigators can relate the level of immune response to the treatment.


Eligibility criteria:
inclusion criteria: * subject has a confirmed diagnosis of mucopolysaccharidosis type ii (mps ii) or hunter syndrome based on enzyme activity and variant analysis. * subject who plan to receive or have received enzyme replacement therapy with idursulfase. exclusion criteria: * none

Keywords: mps ii mucopolysaccharidosis ii hunter syndrome
evaluation of intranasal naltrexone and naloxone

Conditions: Opioid-use Disorder

Summary: this study will be to determine the pharmacokinetics of naltrexone and naloxone when administered via intranasal separately and in combination in healthy volunteers.


Eligibility criteria:
inclusion criteria: * males and females 18 to 55 years of age, inclusive. * provide written informed consent. * body mass index (bmi) ranging from 18 to 30 kg/m2, inclusive. * adequate venous access. * no clinically significant concurrent medical conditions determined by medical history, physical examination, clinical laboratory examination, vital signs, and 12-lead ecg. * agree to use a reliable double-barrier method of birth control from the start of screening until one week after completing the study. oral contraceptives are prohibited. * agree not to ingest alcohol, drinks containing xanthine \>500 mg/day (e.g., coca cola®, tea, coffee, etc.), or grapefruit/grapefruit juice or participate in strenuous exercise 72 hours prior to admission through the last blood draw of the study. exclusion criteria: * contact site for more information
cardiolite-413: a study for patients who had a pci for an acute mi

Conditions: Myocardial Infarction

Summary: the purpose of this clinical study is to learn if there are any changes in how blood gets to your heart muscle and if your heart size changed after your heart attack.


Eligibility criteria:
inclusion criteria: * undergoing primary or rescue pci for acute mi with ecg evidence of a large territory at risk. exclusion criteria: * history of prior mi or cabg surgery, persistent lbbb, atrial fibrillation, end stage renal disease, weight \> 350 lbs.
using national university cancer institute of singapore (ncis) registry to measure time trends in quality of care for breast cancer patients in a national cancer centre

Conditions: Breast Cancer

Summary: the investigators hypothesise that the research data will enable them to elucidate local clinical practices with regard to breast cancer care and enable them to extrpolate the data to improved local clinical care for their patients through self-regulation and audit.


Eligibility criteria:
inclusion criteria: * female * 21 years old exclusion criteria: no patient involved
nac for promoting hematopoietic recovery in patients with acute myeloid leukemia after chemotherapy

Conditions: Acute Myeloid Leukemia

Summary: this is a prospective single-arm clinical study to evaluate the role of nac after chemotherapy among patients with aml can promote hematopoietic recovery and does not affect the remission rate of the leukemia.

hematopoietic recovery after chemotherapy is an important factor affecting the prognosis of acute myeloid leukemia. a previous clinical prospective cohort study showed that nac could improve the function of bone marrow endothelial progenitor cells after chemotherapy, without affecting leukemia cells. previous animal models have found that chemotherapy can reverse the function of bone marrow endothelial cells in classic aml mice. nac promotes hematopoietic recovery in aml mice by improving the bone marrow endothelial cells reversed by chemotherapy. therefore, we hypothesized that the prophylactic administration of nac after chemotherapy could facilitate the recovery of hematopoietic capacity by improving the bone marrow microenvironment of patients with aml.

Eligibility criteria:
inclusion criteria: 1. newly diagnosed aml (except aml-m3) 2. low-, intermediate risk aml (according to 2022 eln) 3. aged 18-60 4. no severe organ injury 1) creatinine \< 1.5mg/dl 2) hemobilirubin ≤ 1.5 x uln 3) ast and alt ≤ 3.0 x uln 4) cardiac ejection index ≥ 50% 5. no uncontrolled active infections 6. sign informed consent form, have the ability to comply with study and follow-up procedures exclusion criteria: 1. hypersensitivity to nac 2. history of bronchial asthma
platelet rich fibrin versus melatonin around dental implants

Conditions: Patients With Missing Teeth

Summary: dental implant is a dental treatment that allow oral rehabilitation for partial and fully edentulous patients. osteointegration is the factor that control success s or failure of dental implant that can be improved by addition of different adjunctive biological materials. platelets rich fibrin plays a significant role in tissue regeneration and wound healing. melatonin is biological hormone that secreted from pineal gland and played an important role in human growth.


Eligibility criteria:
inclusion criteria: 1. good oral hygiene participants, 2. free of any systemic diseases, 3. patients' age ranged from 20 to 40 years old. 4. patients who can complete surgery and the study protocol. 5. partially edentulous patients in the posterior mandibular region (at least a single-mandibular edentulous area) with periodontal health. exclusion criteria: 1. patients who had parafunctional habits, 2. current and former smokers, pregnant 3. lactating women 4. unmotivated patients 5. patients with psychological problems 6. patients who were not able to follow the treatment protocol -
comprehensive geriatric assessment and complications following lung resection for lung cancer

Conditions: Carcinoma, Non-Small-Cell Lung

Summary: schema : prospective prognostic study the main objective is to study the value of the comprehensive geriatric assessment in predicting the risk of post operative complications after lung resection for cancer.

primary outcome : post-operative morbidity at 30-day : post operative complications occurred during 30 days post surgery, evaluated with ctcae v3.0, and complications grade 2.3.4 will be analyzed from day 1, at day 20 up to day 30. evaluation : pre operative : day -30 to day 0, post operative : day 10, day 30, day 90, day 360. secondary outcome : post-operative mortality, length of post operative hospital stay, length of intensive care unit stay, qol assessment, one year survival.

Eligibility criteria:
inclusion criteria: * patient 70 years and more * lung tumour of clinical staging i to iiib receiving curative lung resection exclusion criteria: * diagnosis of non small lung cancer invalidated by the histological findings of the operative sample * psychological conditions, social support or geographical conditions not allowing the study follow up * pre operative chemotherapy or radiotherapy

Keywords: nsc lung cancer,elderly patients,post operative,
tecemotide (l-blp25) in prostate cancer

Conditions: Prostate Cancer

Summary: this study examines tecemotide (l-blp25) in combination with standard treatment for prostate cancer.


Eligibility criteria:
inclusion criteria: * histopathologic documentation of prostate cancer confirmed at the institution of study enrollment prior to starting this study * newly diagnosed or previously untreated prostate cancer with intermediate or high risk features as defined in the protocol * no evidence of metastatic disease on computed tomography (ct) / magnetic resonance imaging (mri) or bone scans * no systemic steroid use within 2 weeks prior to initiation of experimental therapy. limited doses of systemic steroids to prevent intravenous contrast, allergic reaction or anaphylaxis (in subjects who have known contrast allergies) are allowed * eastern co-operative oncology group (ecog) performance status of 0-1 * human leukocyte antigen (hla)-a2 or a3 positive for immunologic monitoring * hematological and biochemical eligibility parameters as defined in the protocol * no other active malignancies within the past 3 years (with the exception of non-melanoma skin cancers or carcinoma in situ of the bladder) * willing to travel to the study center(s) for follow-up visits * age greater than or equal to 18 years old * able to understand and sign informed consent * must agree to use effective birth control (such as a condom) or abstinence during and for a period of 4 months after the last administration of immunotherapy exclusion criteria: * no evidence of being immunocompromised by human immunodeficiency virus, a medical condition requiring systemic steroids, a medical condition requiring immunosuppressive therapy, splenectomy * active hepatitis b or hepatitis c * subjects should have no autoimmune diseases that have required treatment as specified in the protocol * history of immunodeficiency diseases, hereditary or congenital immunodeficiencies * serious intercurrent medical illness * a clinically significant cardiac disease * subjects who have received any prior therapy for prostate cancer * subjects who have known brain metastasis, or with a history of seizures, encephalitis, or multiple sclerosis * subjects receiving any other investigational agents * contraindication to biopsy such as bleeding disorders, ratio of prothrombin time to partial thromboplastin time (pt/ptt) \>=1.5 times the upper limit of normal, artificial heart valve * contraindication to mri such as subjects weighing \>136 kilograms, allergy to magnetic resonance (mr) contrast agent, subjects with pacemakers, cerebral aneurysm clips, shrapnel injury or implantable electronic devices * contraindication to radiation therapy such as pre-existing and active prostatitis or proctitis, inflammatory bowel disease or known genetic sensitivity to ionizing radiation, or history of prior radiation to the pelvis

Keywords: tecemotide prostate cancer goserelin cyclophosphamide radiotherapy
to evaluate the safety and efficacy of sofosbuvir and ribavirin in patients with hcv (genotype 3) related decompensated cirrhosis

Conditions: HCV Related Cirrhosis

Summary: in this prospective randomized trial, a minimum of 300 consecutive patients of decompensated hcv (hepatitis c virus) related cirrhosis, presenting to the institute of liver and biliary sciences hospital will be included and those patients meeting the entry criteria received treatment with 400 mg of sofosbuvir, administered orally once daily, and ribavirin administered orally twice daily, with doses determined according to body weight(600 mg daily in patients with a body weight of ≤60 kg,800 mg daily in patients weighing \>60 and ≤80 kg, and1000 mg daily in patients with a body weight of \>80 kg). based on the treatment duration, patients would be randomized in either of the 3 treatment groups - * group 1 - sofosbuvir + ribavirin x 24 weeks * group 2 - sofosbuvir + ribavirin x 36 weeks * group 3 - sofosbuvir + ribavirin x 48 weeks


Eligibility criteria:
inclusion criteria: * male or female ≥ 18 yrs * baseline hcv rna \> 1000 iu/ml * cirrhosis with current or prior decompensation * hcv (hepatitis c infection) genotype 3 * treatment naïve or treatment experienced exclusion criteria: * hiv or hbv (hepatitis b virus) co-infection * recent variceal bleed * pregnancy * haemolytic anaemia * platelet counts \<20,000/ml * advanced hcc (hepatocellular carcinoma) * renal dysfunction, gfr (glomerular filtration rate) \< 30 ml/min * haemoglobin \< 10 g/dl * meld (model for end stage liver disease) \>25, ctp (child-turcotte-pugh score) \>12 * post organ transplant
the 3d cohort study (design, develop, discover)

Conditions: Pregnancy Outcome

Summary: the 3d cohort study (design, develop, discover) was established to help bridge knowledge gaps about the links between various adverse exposures during pregnancy with birth outcomes and later health outcomes in children.

the main objective of the 3d study is to create a large pregnancy and birth cohort, allowing for the assessment of the effects of combined prenatal exposure on both birth outcomes and longer-term infant and child health. the specific objectives are to: 1. determine the effects of pre- and post-natal exposures to environmental contaminants, nutritional factors and psychosocial stress on pregnancy and neurodevelopmental outcomes; 2. assess the contribution of social, genetic, epigenetic, nutritional and environmental factors to the etiology and outcomes of intrauterine growth restriction (iugr) and preterm birth; and 3. assess the effects of assisted reproductive technologies (art) on indicators of epigenetic modifications, and the relationship between such epigenetic changes and infant neurodevelopmental, cardiovascular, and metabolic outcomes.

Eligibility criteria:
inclusion criteria: * able to communicate in french or english exclusion criteria: * current intravenous drug use * severe illnesses or life threatening conditions * multiple gestation pregnancies

Keywords: intrauterine growth restriction preterm birth birth defect infant growth neurodevelopmental outcomes
cohort study of hiv-1 incidence among clients of the thai red cross aids research center, bangkok, thailand

Conditions: HIV Infections

Summary: the purpose of this study is to assess populations in thailand at high risk for hiv-1 infection for potential efficacy trials of candidate hiv vaccines to include: 1. assess incidence of hiv-1 and volunteer retention 2. describe early viral load and cd4 counts 3. assess participant willingness to participate in hiv vaccine efficacy trials and other hiv prevention trials 4. describe volunteer risk behavior

prospective cohort study of hiv-negative participants who will receive voluntary counseling and testing (vct) for hiv-antibody in conjunction with questionnaires on risk behavior, willingness to participate in hiv vaccine trials and other hiv prevention trials at 4 month intervals for a period of 1 year. this study will follow 1000 hiv-negative volunteers with an expected minimum of 15-20 incident hiv-infections based on a minimum incidence rate of 1.5/100 person-years. weighted incidence estimates will be calculated with exact 95% confidence intervals.

Eligibility criteria:
inclusion criteria: * man or woman aged 18-50 years * willing to provide location or contact information and allow contact * thai citizenship as identified by thai national identification card * ability and willingness to provide consent * availability for follow-up for the planned study duration exclusion criteria: * persons who have a history of a medical or psychiatric disorder, that in the judgment of the investigator(s), would interfere with or serve as a contraindication to adherence to the study protocol or ability to give informed consent * persons who are known to be hiv-positive

Keywords: hiv-negative male and female clients ages 18-50 years seeking hiv counseling testing at trcarc